Literature DB >> 18452806

Chronic Lyme disease: a review.

Adriana Marques1.   

Abstract

Studies have shown that most patients diagnosed with chronic Lyme disease either have no objective evidence of previous or current infection with Borrelia burgdorferi or are patients who should be classified as having post-Lyme disease syndrome, which is defined as continuing or relapsing nonspecific symptoms (such as fatigue, musculoskeletal pain, and cognitive complaints) in a patient previously treated for Lyme disease. Despite extensive study, there is currently no clear evidence that post-Lyme disease syndrome is caused by persistent infection with B burgdorferi. Four randomized placebo-controlled studies have shown that antibiotic therapy offers no sustained benefit to patients who have post-Lyme disease syndrome. These studies also showed a substantial placebo effect and a significant risk of treatment-related adverse events. Further research to elucidate the mechanisms underlying persistent symptoms after Lyme disease and controlled trials of new approaches to the treatment and management of these patients are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452806      PMCID: PMC2430045          DOI: 10.1016/j.idc.2007.12.011

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  78 in total

1.  Culture Borrelia burgdorferi.

Authors:  R C Tilton; D Barden; M Sand
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

Review 2.  A critical appraisal of "chronic Lyme disease".

Authors:  Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

3.  Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans.

Authors:  K Weber; V Preac-Mursic; U Neubert; R Thurmayr; P Herzer; B Wilske; G Schierz; W Marget
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

4.  Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease.

Authors:  N A Shadick; C B Phillips; O Sangha; E L Logigian; R F Kaplan; E A Wright; A H Fossel; K Fossel; V Berardi; R A Lew; M H Liang
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

5.  Treatment of the early manifestations of Lyme disease.

Authors:  A C Steere; G J Hutchinson; D W Rahn; L H Sigal; J E Craft; E T DeSanna; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

6.  Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.

Authors:  Heta Yrjänäinen; Jukka Hytönen; Xiao-yu R Song; Jarmo Oksi; Kaija Hartiala; Matti K Viljanen
Journal:  J Infect Dis       Date:  2007-04-06       Impact factor: 5.226

7.  Summary of the first 100 patients seen at a Lyme disease referral center.

Authors:  L H Sigal
Journal:  Am J Med       Date:  1990-06       Impact factor: 4.965

8.  Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; E Schielke; F Sörgel; K M Einhäupl
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

Review 9.  Lyme disease: an infectious and postinfectious syndrome.

Authors:  E S Asch; D I Bujak; M Weiss; M G Peterson; A Weinstein
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

10.  Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations.

Authors:  Holger J Schünemann; Atle Fretheim; Andrew D Oxman
Journal:  Health Res Policy Syst       Date:  2006-12-05
View more
  55 in total

1.  Remains of infection.

Authors:  Alan Barbour
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

2.  Prolonged antibiotic use induces intestinal injury in mice that is repaired after removing antibiotic pressure: implications for empiric antibiotic therapy.

Authors:  Lindsey E Romick-Rosendale; Anne Legomarcino; Neil B Patel; Ardythe L Morrow; Michael A Kennedy
Journal:  Metabolomics       Date:  2014-02       Impact factor: 4.290

3.  CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study.

Authors:  John N Aucott; Mark J Soloski; Alison W Rebman; Lauren A Crowder; Lauren J Lahey; Catriona A Wagner; William H Robinson; Kathleen T Bechtold
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

4.  HtrA, a Temperature- and Stationary Phase-Activated Protease Involved in Maturation of a Key Microbial Virulence Determinant, Facilitates Borrelia burgdorferi Infection in Mammalian Hosts.

Authors:  Meiping Ye; Kavita Sharma; Meghna Thakur; Alexis A Smith; Ozlem Buyuktanir; Xuwu Xiang; Xiuli Yang; Kamoltip Promnares; Yongliang Lou; X Frank Yang; Utpal Pal
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

5.  Screening of NCI-DTP library to identify new drug candidates for Borrelia burgdorferi.

Authors:  Venkata Raveendra Pothineni; Dhananjay Wagh; Mustafeez Mujtaba Babar; Mohammed Inayathullah; R Edward Watts; Kwang-Min Kim; Mansi B Parekh; Abhijit Achyut Gurjarpadhye; David Solow-Cordero; Lobat Tayebi; Jayakumar Rajadas
Journal:  J Antibiot (Tokyo)       Date:  2016-11-09       Impact factor: 2.649

Review 6.  Lyme Borreliosis: Is there a preexisting (natural) variation in antimicrobial susceptibility among Borrelia burgdorferi strains?

Authors:  Emir Hodzic
Journal:  Bosn J Basic Med Sci       Date:  2015-07-08       Impact factor: 3.363

7.  Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease.

Authors:  Peter D Burbelo; Alexandra T Issa; Kathryn H Ching; Jeffrey I Cohen; Michael J Iadarola; Adriana Marques
Journal:  Clin Vaccine Immunol       Date:  2010-04-14

8.  Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls.

Authors:  Adriana Marques; Margaret R Brown; Thomas A Fleisher
Journal:  Clin Vaccine Immunol       Date:  2009-06-10

9.  Detecting Lyme disease using antibody-functionalized single-walled carbon nanotube transistors.

Authors:  Mitchell B Lerner; Jennifer Dailey; Brett R Goldsmith; Dustin Brisson; A T Charlie Johnson
Journal:  Biosens Bioelectron       Date:  2013-02-04       Impact factor: 10.618

10.  Association of immune response to endothelial cell growth factor with early disseminated and late manifestations of Lyme disease but not posttreatment Lyme disease syndrome.

Authors:  Kevin S Tang; Mark S Klempner; Gary P Wormser; Adriana R Marques; Armin Alaedini
Journal:  Clin Infect Dis       Date:  2015-07-28       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.